Placebo to AIN457 150mg/1mL Solution for injection in pre-filled syringe
Sponsors
Novartis Pharma AG
Conditions
Giant cell arteritis (GCA)Moderate to severe rotator cuff tendinopathy
Phase 3
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy
CompletedCTIS2022-502068-19-00
Start: 2023-11-16End: 2024-10-15Target: 81Updated: 2024-04-22
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy
CompletedCTIS2022-502080-38-00
Start: 2023-10-16End: 2024-12-05Target: 128Updated: 2024-06-03
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
SuspendedCTIS2024-510744-31-00
Start: 2021-10-06Target: 243Updated: 2025-12-11